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Differential Gene Expression Profiles May Differentiate
Responder and Nonresponder Patients with
Rheumatoid Arthritis for Methotrexate (MTX)
Monotherapy and MTX plus Tumor Necrosis Factor
Inhibitor Combined Therapy
RENÊ DONIZETI RIBEIRO OLIVEIRA, VANESSA FONTANA, CRISTINA MORAES JUNTA, 
MÁRCIA MARIA CHIQUITELLI MARQUES, CLÁUDIA MACEDO, DIANE MEYRE RASSI, 
GERALDO ALEIXO PASSOS, EDUARDO ANTONIO DONADI, and PAULO LOUZADA-JUNIOR
ABSTRACT. Objective. We aimed to evaluate whether the differential gene expression profiles of patients with
rheumatoid arthritis (RA) could distinguish responders from nonresponders to methotrexate (MTX)
and, in the case of MTX nonresponders, responsiveness to MTX plus anti-tumor necrosis factor-α
(anti-TNF) combined therapy. 
Methods.We evaluated 25 patients with RA taking MTX 15–20 mg/week as a monotherapy (8 respon-
ders and 17 nonresponders). All MTX nonresponders received infliximab and were reassessed after 20
weeks to evaluate their anti-TNF responsiveness using the European League Against Rheumatism
response criteria. A differential gene expression analysis from peripheral blood mononuclear cells was
performed in terms of hierarchical gene clustering, and an evaluation of differentially expressed genes
was performed using the significance analysis of microarrays program. 
Results. Hierarchical gene expression clustering discriminated MTX responders from nonresponders,
and MTX plus anti-TNF responders from nonresponders. The evaluation of only highly modulated
genes (fold change > 1.3 or < 0.7) yielded 5 induced (4 antiapoptotic and CCL4) and 4 repressed 
(4 proapoptotic) genes in MTX nonresponders compared to responders. In MTX plus anti-TNF non -
responders, the CCL4, CD83, and BCL2A1 genes were induced in relation to responders.
Conclusion. Study of the gene expression profiles of RA peripheral blood cells permitted differentia-
tion of responders from nonresponders to MTX and anti-TNF. Several candidate genes in MTX
non-responders (CCL4, HTRA2, PRKCD, BCL2A1, CAV1, TNIP1, CASP8AP2,MXD1, and BTG2) and
3 genes in MTX plus anti-TNF nonresponders (CCL4, CD83, and BCL2A1) were identified for further
study. (First Release July 1 2012; J Rheumatol 2012;39:1524–32; doi:10.3899/jrheum.120092)
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Rheumatoid arthritis (RA) is an inflammatory autoimmune
disease characterized by chronic and deforming polyarthritis
that is accompanied by systemic involvement in many
patients. Multiple clinical features and heterogeneous therapy
responses may be influenced by genetic, environmental, and
immunologic factors1. Although some of these features have
been used for disease stratification and disease outcome pre-
diction2,3, they have failed to predict the response to
 treatment.
Methotrexate (MTX) remains the standard therapy for
RA4, and despite the introduction of other disease-modifying
antirheumatic drugs (DMARD), the remission rate for MTX
treatment is < 65%5. Although pharmacogenomic analyses
have been useful in predicting adverse events6, there are few
data about the prediction of the response to MTX. Wessels, et
al7 developed a clinical pharmacogenetic model to predict the
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response to MTX in RA patients without any previous treat-
ment. They found that clinical characteristics in association
with some polymorphisms of 4 genes involved in the mecha-
nism of action of MTX could predict the response in 60% of
the patients with higher or lower disease activity as evaluated
by Disease Activity Score (DAS). Although this attempt
seems interesting, clinical characteristics [DAS, smoking sta-
tus, and rheumatoid factor (RF) positivity] still make up the
most important portion of the model.
Clinical studies on the efficacy of anti-tumor necrosis fac-
tor-α (anti-TNF) agents have shown that about 30% of
patients receiving this therapy are nonresponders3,5. While
many efforts have been made to identify biomarkers for ther-
apy response6, there is no single clinical or laboratory marker
that enables an individual prediction of efficacy for MTX and
anti-TNF therapy8,9,10.
Peripheral blood cells may be suitable for analyzing differ-
ential gene expression profiles, providing a framework for
selecting clinically relevant biomarkers in RA11 and distin-
guishing patients with RA in terms of immunogenetics and
treatment features12. In this context, transcription signature
profiles have been used to predict responses to anti-TNF
agents in RA13,14; however, there has been no study evaluat-
ing differential gene profiles in MTX monotherapy responders
and nonresponders. A better understanding of the differential
gene profile on the influence of MTX treatment may be help-
ful in the identification of patients with RA who are most like-
ly to benefit from MTX treatment. We aimed to evaluate
whether peripheral blood mononuclear cell (PBMC) differen-
tial gene expression profile analysis could distinguish
between RA responders and nonresponders to MTX
monotherapy. In addition, we also evaluated the transcription
profiles of MTX nonresponders who turned to MTX plus anti-
TNF therapy, to distinguish further between responders and
nonresponders to anti-TNF therapy.
MATERIALS AND METHODS
We evaluated 25 patients who fulfilled the 1987 revised American College of
Rheumatology criteria for RA classification15. At the beginning of our study,
all patients were receiving MTX monotherapy 15–20 mg/week and pred-
nisone 5 mg/day. MTX responders had been receiving it for up to 2 years and
MTX nonresponders for 16 weeks. The dose of both drugs was stable for at
least 8 weeks before the start of the study and was maintained until the end of
it. No patient received a DMARD other than MTX before or during the study.
Patients were classified as MTX responders or nonresponders and anti-TNF
responders or nonresponders, according to European League Against
Rheumatism (EULAR) criteria16, defining 8 patients as MTX responders and
17 as MTX nonresponders. MTX nonresponders additionally received inflix-
imab intravenously at a dose of 3 mg/kg at 0, 2, 6, and 14 weeks. No patient had
received biological treatment before infliximab. These patients were clinically
reassessed after 20 weeks of treatment to evaluate the response to anti-TNF
agent, according to EULAR criteria16. The activity of the disease was measured
using the DAS28 (DAS, including a 28-joint count). Blood samples were
obtained at the beginning of the study, before the use of anti-TNF therapy.
All patients provided informed consent to participate in the study, which
was approved by the local Ethics Committee (protocol 2958/2005). Patients
were excluded if they presented other autoimmune or rheumatic diseases,
infectious disorders, or positive serology for Chagas disease, hepatitis B or C,
or human immunodeficiency virus infection.
Autoantibody analyses. RF was detected by nephelometry, and the test was
considered positive at concentrations > 10 IU/ml. Anticitrullinated protein
antibody (ACPA) immunoglobulin G (IgG) detection was performed using
commercial ELISA kits according to the manufacturer’s instructions (Quanta
Lite anti-CCP 2; Inova, San Diego, CA, USA) and was considered positive at
concentrations > 20 IU/ml.
HLA-DRB1 typing. HLA-DRB1 typing was performed using polymerase
chain reaction (PCR)-amplified DNA hybridized with sequence-specific
primers using commercial kits (One-Lambda, Canoga Park, CA, USA). DNA
was extracted from PBMC obtained after separation on a Ficoll-Hypaque
density gradient (Sigma, St. Louis, MO, USA). Individuals carrying certain
HLA-DRB1 typing — *01:01, *01:02, *04:01, *04:04, *04:05, *04:08,
*10:01, and *14:02 alleles — were considered to pertain to the shared epitope
(HLA-SE) group, and they were classified as SE-positive.
RNA extraction and preparation. Twenty milliliters of whole blood was
obtained from each individual using Vacutainer-heparin tubes. After separa-
tion with Ficoll-Hypaque gradient centrifugation, Trizol reagent (Invitrogen,
Carlsbad, CA, USA) was used to extract total RNA from PBMC, following
the manufacturer’s instructions. The quality of RNA samples was evaluated
using denaturing agarose gel electrophoresis under standard conditions.
Preparation of cDNA microarray. Glass slide cDNA microarrays were pre-
pared on saline-coated Ultra GAPS slides (Corning, Lowell, MA, USA) and
were used to evaluate gene expression. The 4500 cDNA sequences were
retrieved from the human expressed sequence tag cDNA library (www.life-
sciences.sourcebioscience.com). Microarrays were prepared based on pub-
lished protocols using PCR from the cDNA clones17 with a Generation III
Array Spotter (Amersham Molecular Dynamics, Sunnyvale, CA, USA). The
cDNA complex probes derived from patients with RA and from a reference
sample were prepared by reverse transcription using 10-µg total RNA and
labeled with Cy3 fluorochrome using the CyScribe postlabeling kit (GE
Healthcare Life Sciences, Buckinghamshire, UK). Fifteen hours were
required for hybridization, followed by washing using an automatic slide
processor system (Amersham Biosciences). Microarrays were scanned using
a Generation III laser scanner (Amersham Biosciences). Equimolar quantities
of cDNA obtained from the total RNA of different human cell strains (Jurkat,
Hela, HEp-2, and U343) were used as references for the hybridization. This
approach allowed estimation of the relative amount of cDNA target sequences
in each microarray spot.
Statistical analyses and clinical and laboratory characteristics of the patients.
Student’s t test and Fisher’s exact test were used to examine group homogene-
ity. The comparisons between different groups regarding age, time of disease,
and DAS28 at baseline and after 20 weeks were performed using a 2-sample t
test. Fisher’s exact test and contingency tables were used to compare differ-
ences between different groups regarding sex, smoking habits, RF, ACPA, and
HLA-SE. For all tests, results were considered significant at p < 0.05.
Analysis of cDNA microarray data. Microarray image quantification was per-
formed using Spotfinder software (Dana-Farber Cancer Institute, Boston,
MA, USA; http://www.tm4.org/). The normalization process was carried out
using the R platform, and statistical data were analyzed using Multi -
experiment Viewer software (version 3.1; both available from R Foundation
for Statistical Computing, Vienna, Austria; www.r-project.org)18.
The significance analysis of microarrays (SAM) method was used for
each independent sample, assigning a score to each gene on the basis of the
change in gene expression relative to the SD of repeated measurements. The
SAM method uses permutations of the repeated measurements to estimate the
percentage of genes identified by chance, i.e., the false discovery rate (FDR
= 0.005); its objective is to construct a scatterplot displaying the induced and
repressed genes. The program is available at www-stat.stanford.edu/
~tibs/SAM/19. The data mining of the genes was performed using the
SOURCE databases (Genetics Department, Stanford University, Palo Alto,
CA, USA; smd-www.stanford.edu/cgi-bin/source/sourceSearch) and DAVID
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(National Institute of Allergy and Infectious Diseases, Frederick, MD, USA;
david.abcc.ncifcrf.gov). For all comparisons, only genes expressed in at least
80% of the microarray platform were considered analyzed. The microarray
experimental plan and data analysis in this study are in accordance with the
“minimum information about a microarray experiment” guidelines. The
microarray data presented here have been deposited in a public repository, the
European Bioinformatics Institute (Wellcome Trust Genome Campus,
Cambridge, UK; available from www.ebi.ac.uk/arrayexpress; ArrayExpress
accession: E-MEXP-3390). 
RESULTS
The clinical and laboratory features of the patients with RA
are shown in Table 1. The comparisons of demographic, clin-
ical, and laboratory variables between MTX responders and
nonresponders revealed no significant differences (Table 2).
Similarly, the comparisons of these variables between respon-
ders and nonresponders to anti-TNF agents revealed non-
significant differences, except for the presence of HLA-SE,
which was more frequent in nonresponders to anti-TNF
agents (p = 0.03; Table 2).
The nonpaired differential gene expression analysis was
performed in 2 ways. First, we compared the transcription
profile between responders (n = 8) and nonresponders (n = 17)
to MTX, and second, we analyzed only the nonresponders to
MTX, stratified according to the response or lack of a
response to TNF agents. When we compared MTX responders
with nonresponders, we observed 535 significant and differ-
entially expressed genes (248 induced and 287 repressed).
Overall, modulated genes were primarily implicated in cellu-
lar signal transduction, regulation of transcription, protein
metabolism, apoptosis regulation, and cell proliferation. The
major biological functions of the induced genes included sig-
nal transduction (20%), regulation of transcription (12%), cell
proliferation (8%), and protein metabolism (8%), whereas the
repressed genes were related to signal transduction (16%),
regulation of transcription (12%), protein metabolism (11%),
and apoptosis (9%), as shown in Figure 1.
Overall, hierarchical clustering of the gene expression pro-
file analysis separated responders from nonresponders to
MTX monotherapy (Figure 2). The upper part of the heat map
shown in Figure 2 exhibits a cloud of genes that were induced
in responders and repressed in nonresponders to MTX, where-
as the lower part of the map shows the inverse. To select rele-
vant genes to be discussed, we pinpointed genes that were
visually modulated in responders in relation to nonresponders
according to the results observed in the heat map. In addition
to the qualitative analysis, to restrict the number of highly
modulated genes, we selected only the genes for which the
magnitude of expression was > 1.3 or < 0.7 (fold change > 1.3
or < 0.7), yielding 9 modulated genes (5 induced and 4
repressed). Among the repressed genes, all were involved in
Table 1. Demographic, clinical, laboratory, and genetic features of patients with rheumatoid arthritis.
Groups Patient Age/Sex Disease RF/ HLA- HLA- Anti-TNF DAS28 DAS28 Response
Duration, ACPA DRB1 Present Agent After MTX After 20 to Anti-
yrs Allele Treatment Weeks TNF Agent
MTX responders, 1 58 M 3 Pos/pos 01:01/04:01 Yes None 0.14 NA NA
n = 8 2 71 F 6 Pos/pos 13:01/03:01 No None 2.52 NA NA
3 64 M 7 Pos/pos 01:02/03:01 Yes None 2.05 NA NA
4 66 F 2 Pos/neg 03:01/16:01 No None 1.89 NA NA
5 47 F 12 Pos/pos 04:04/04:01 Yes None 2.37 NA NA
6 40 F 2 Pos/pos 04:04/13:01 Yes None 2.24 NA NA
7 37 F 7 Pos/pos 04:01/07:01 Yes None 2.25 NA NA
8 55 F 14 Neg/neg 14:02/16:01 Yes None 1.54 NA NA
MTX nonresponders, 9 47 F 7 Pos/neg 03:01/13:01 No Infliximab 5.23 2.52 Yes
n = 17 10 65 F 11 Pos/pos 01:01/07:01 Yes Infliximab 7.23 2.05 Yes
11 56 M 12 Pos/pos 13:01/15:01 No Infliximab 7.43 3.46 Yes
12 41 F 1 Pos/pos 03:01/07:01 No Infliximab 7.96 3.56 Yes
13 67 M 6 Neg/pos 04:01/11:01 Yes Infliximab 6.02 3.56 Yes
14 64 F 1 Neg/pos 11:01/13:01 No Infliximab 7.24 2.78 Yes
15 61 F 10 Neg/neg 03:01/11:01 No Infliximab 5.3 2.43 Yes
16 59 F 6 Neg/neg 01:01/14:01 Yes Infliximab 5.97 2.79 Yes
17 29 F 8 Neg/pos 01:01/14:01 Yes Infliximab 5.39 2.32 Yes
18 46 M 2 Pos/pos 04:01/07:01 Yes Infliximab 6.57 6.2 No
19 38 F 9 Pos/pos 01:02/03:01 Yes Infliximab 6.06 5.71 No
20 39 M 2 Pos/pos 04:01/04:04 Yes Infliximab 8.76 7.77 No
21 62 F 3 Pos/pos 01:01/16:01 Yes Infliximab 6.74 6.88 No
22 51 F 1 Pos/pos 10:01/12:01 Yes Infliximab 6.5 5.78 No
23 53 F 2 Neg/pos 01:02/07:01 Yes Infliximab 6 5.9 No
24 55 F 6 Neg/pos 04:01/10:01 Yes Infliximab 7.03 6.13 No
25 34 F 3 Pos/pos 04:01/04:01 Yes Infliximab 4.66 3.55 No
MTX: methotrexate; TNF: tumor necrosis factor; RF: rheumatoid factor; ACPA: anticitrullinated protein antibodies; HLA-SE: shared epitope of HLA-DRB1:
DAS28: 28-joint count Disease Activity Score; NA: not applicable.
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proapoptotic processes, including protein kinase DNA-acti-
vated catalytic polypeptide (PRKDC), caspase 8 associated
protein 2 (CASP8AP2), caveolin 1 (CAV1), and HtrA serine
peptidase 2 (HTRA2). Four out of 5 induced genes were
involved in antiapoptotic processes, including BCL2-related
protein A1 (BCL2A1), BTG family member 2 (BTG2),
TNFAIP3 interacting protein 1 (TNIP1), and MAX dimeriza-
tion protein 1 (MXD1). In addition, we observed 1 induced
gene involved in immune response and inflammation
[chemokine (C-C motif) ligand 4 (CCL4); Table 3].
All patients who failed to respond to MTX (n = 17) addi-
tionally received infliximab, and after 20 weeks of treatment,
9 were classified as responders and 8 were classified as non-
responders to the anti-TNF agent (Table 1). The comparisons
of the transcription profiles of responders to nonresponders to
anti-TNF agents disclosed 288 differentially expressed genes
(192 induced and 96 repressed), which were implicated in sig-
nal transduction, regulation of transcription, cell cycle, protein
metabolism, and apoptosis regulation. The biological func-
tions of the induced genes included signal transduction (14%),
regulation of transcription (13%), protein metabolism (11%),
cell cycle (9%), and apoptosis (9%), whereas the repressed
genes were related to the regulation of transcription (13%),
signal transduction (12%), cell cycle (11%), protein metabo-
lism (9%), and apoptosis (9%; Figure 3).
The second hierarchical clustering analysis performed
Table 2. Clinical and laboratory features of patients with rheumatoid arthritis stratified according to their responsiveness [responders (R) or nonresponders
(NR)] to methotrexate (MTX) as monotherapy or MTX plus anti-TNF-agent combined therapy.
Features MTX-R, MTX-NR, p MTX-NR + MTX-NR + p
n = 8 n = 17 TNF-R, n = 9 TNF-NR, n = 8
Age, yrs, mean (range) 54.7 (37–71) 51 (29–67) NSa 54.3 (29-67) 47.2 (34–62) NSa
Women/men 4/1 3/1 NSb 4.5/1 4/1 NSb
Disease duration, yrs 6.6 5.4 NSa 6.9 3.5 NSa
Smoker, % 38 53 NSb 44 50 NSb
RF+, % 88 65 NSb 56 75 NSb
ACPA+, % 75 82 NSb 67 100 NSb
HLA-SE+, % 75.0 70 NSb 44 100.0 0.03b
DAS28 at baseline, mean ± SD 1.87 ± 0.76 6.47 ± 1.1 < 0.0001a 6.42 ± 1.05 6.54 ± 1.1 NSa
DAS28 after 20 weeks, mean ± SD NA NA 2.83 ± 0.57 5.99 ± 1.20 < 0.0001a
MTX, mg/wk, range 15–20 15–20 15–20 15–20
Prednisone, mg/day 5 5 5 5
a 2-sample t test; b Fisher’s exact test. MTX-R: responders to methotrexate; MTX-NR: nonresponders to MTX: MTX-NR + TNF-R: nonresponders to MTX
but responders to anti-tumor necrosis factor (TNF) agent; MTX-NR + TNF-NR: nonresponders to MTX and nonresponders to anti-TNF agent; RF: rheuma-
toid factor; ACPA: anticitrullinated protein antibodies; HLA-SE: shared epitope of HLA-DRB1; DAS28: Disease Activity Score including a 28-joint count;
NS: not significant; NA: not applicable.
Figure 1. Major biological functions of the 535 modulated genes obtained after comparison between patients with RA who were responders and those who were
nonresponders to MTX monotherapy. A. The 238 induced genes. B. The 287 repressed genes.
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among responders and nonresponders to the anti-TNF agents
clearly grouped these patients in separate clusters, as shown in
Figure 4. The visual analysis of the heat map, also shown in
Figure 4, shows a cluster of induced genes (upper part of the
figure) and a cluster of repressed genes (lower part of the fig-
ure) in the nonresponder group. Regarding the profile of the
responder group, a cloud of repressed genes can be observed
in the middle of Figure 4, and another cloud of induced genes
appears at the bottom. The quantitative analysis, restricted to
genes for which the expression was > 1.3 or < 0.7 (fold change
Figure 2. Hierarchical clustering of differential gene expression in patients with RA, stratified according to
the response to MTX therapy (MTX-R: MTX responders; MTX-NR: MTX nonresponders). The dendrogram
over the heat map shows distinct hybridization profiles for MTX responders and nonresponders.
Table 3. Highly modulated genes (0.7 < fold change > 1.3) observed in patients with RA after comparison between responders (n = 8) and nonresponders 
(n = 17) to methotrexate (MTX) monotherapy.
Symbol Gene Process Fold Change
(MTX-NR vs
MTX-R)
Apoptosis
HTRA2 HtrA serine peptidase 2 Proapoptotic 0.69
CAVI Caveolin 1 Proapaptotic (cell death TNF-induced) 0.65
CASP8AP2 Caspase 8 associated protein 2 Proapoptotic 0.54
PRKDC Protein kinase, DNA-activated, catalytic polypeptide Proapoptotic 0.49
BCL2A1 BCL2-related protein A1 Antiapoptotic 1.62
MXD1 MAX dimerization protein 1 Antiapoptotic 1.43
TNIP1 TNFAIP3 interacting protein 1 Antiapoptotic TNF-dependent 1.35
BTG2 BTG family, member 2 Antiapoptotic 1.32
Immune response
CCL4 Chemokine (C-C motif) ligand 4 Inflammatory response 1.89
MTX-NR: nonresponders to methotrexate; MTX-R: responders to MTX; TNF: tumor necrosis factor.
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> 1.3 or < 0.7), yielded 3 modulated genes; all of these were
repressed. One gene was related to the inhibition of apoptosis
(BCL2A1) and the other 2 were related to immune and inflam-
matory responses [CCL4 and CD83 molecule (CD83); Table
4]. The BCLA2A1 and CCL4 genes were induced in non -
responders to MTX and in nonresponders to anti-TNF agents,
as shown in Tables 3 and 4.
DISCUSSION
The evaluation of differential gene expression profiles has
Figure 3. Major biological functions of the 288 modulated genes obtained after comparison between patients with RA who were responders and those who were
nonresponders to MTX plus anti-TNF agent combined therapy. A. The 192 induced genes. B. The 96 repressed genes.
Figure 4. Hierarchical clustering of differential gene expression in patients with RA stratified according to
response to MTX plus anti-TNF agent combined therapy (R TNF: MTX + anti-TNF agent responders; NR
TNF: MTX + anti-TNF agent nonresponders). The dendrogram over the heat map shows distinct hybridiza-
tion profiles for MTX + anti-TNF agent responders and nonresponders.
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been useful as a tool to discriminate between hybridization
signatures in tissue specimens and in PBMC, which have been
used as reporters of subjacent autoimmune or chronic inflam-
matory disease20. Although tissue and cells obtained from the
site of inflammation may more accurately reflect the patho-
genic features of a disorder, sample accessibility is crucial. In
this regard, peripheral immune cells are key sentinels of host
defense, being used to identify novel disease biomarkers and
treatment response21,22,23.
Because the presence of HLA-SE, RF, and ACPA11,24,25
and coadjuvant RA treatment (particularly with cortico -
steroids26,27), may influence transcription profiles in patients
with RA, it is notable that all these variables were very sim-
ilar between MTX responders and nonresponders. In addi-
tion, the dose of MTX and the type of anti-TNF agents given
was strictly controlled in all patients. The control of demo-
graphic, clinical, laboratory, and treatment features con-
tributed to a better comparison between responders and non-
responders, permitting a more accurate interpretation of the
results.
There is little information regarding the transcription pro-
files of patients with RA who respond or do not respond to
MTX treatment. The only study available in the literature
evaluated the effect of in vitro MTX treatment on RA and on
control synovial fibroblasts, reporting that MTX reversed the
modulated expression of genes related to apoptosis and cell
adhesion in RA fibroblasts to the levels observed in control
fibroblasts28. In our series, despite the small number of
patients, we clearly observed modulation of genes implicated
in apoptosis in MTX nonresponder patients when compared to
responders. Of these genes, 4 were repressed and associated
with proapoptotic mechanisms (HTRA2, CAV1, CASP8AP2,
and PRKDC), and 4 were induced and associated with anti-
apoptotic processes (BCL2A1, MXD1, TNIP1, and BTG2). It
is interesting to observe that 2 of the genes modulated in MTX
nonresponders, 1 proapoptotic (CAV1) and 1 antiapoptotic
(TNIP1), are related to TNF-dependent apoptosis. In addition,
CAV1 was also induced in responders to anti-TNF agents (fold
change 1.23), suggesting that a balance between pro- and anti-
apoptotic genes may contribute to MTX response. Indeed,
MTX reduces cell viability, and this effect may be correlated
with the induction of apoptosis, especially in synovial cells, T
cells, and monocytes from patients with RA29,30; these effects
should be expected in MTX responders. In addition to apop-
tosis, MTX may also suppress T cell activation, mediated in
part by adenosine31. Thus, the lack of response to MTX in
patients with RA may be due to a lack of apoptosis induction
and impairment of T cell suppression, as suggested by Brinker
and Ranganathan6.
Considering the transcription profiles of MTX nonrespon-
ders who received anti-TNF agents (infliximab), various
approaches have been developed to identify a transcript sig-
nature associated with a response to anti-TNF agents in
patients with RA13,32; however, the results have been hetero-
geneous because of several variables, including a lack of
homogeneity of the patients in terms of clinical and laborato-
ry data and the use of coadjuvant therapies13,14. Although
almost all of these variables were controlled in the present
series, HLA-SE was present in all nonresponders and in only
44% of the responders to anti-TNF therapy. HLA-SE is
strongly associated with susceptibility and severity of disease
in patients with RA33,34; however, it has not been identified as
a predictive marker for anti-TNF response35,36. It is empha-
sized that the major focus of our study was evaluation of the
gene profiles associated with MTX therapy, and blood collec-
tion was performed before anti-TNF therapy was adminis-
tered, i.e., the response to that therapy was evaluated 20 weeks
afterward. This approach permitted evaluation of the tran-
scription profiles before administration of the anti-TNF agent
(Figure 4). In this context, the BCL2A1 gene, involved in the
inhibition of apoptosis, was repressed in anti-TNF agent
responders compared with nonresponders (Table 4). In the
first analysis, patients who did not respond to MTX monother-
apy presented induction of the BCL2A1 gene (fold change
1.62) compared with MTX responders (Table 3). This result
indicated that MTX nonresponders, exhibiting downregula-
tion of the BCL2A1 gene, responded to anti-TNF therapy. This
effect could be an additional mechanism of therapeutic
response induced by anti-TNF agents. Because Bcl-2
inhibitors (ABT-737) are small molecules with apoptotic
Table 4.  Highly modulated genes (0.7 < fold change > 1.3) observed in patients with RA after comparison
between responders (n = 9) and nonresponders (n = 8) to methotrexate plus anti-tumor necrosis factor (TNF)
agent combined therapy.
Symbol Gene Process Fold Change
(TNF-R vs
TNF-NR)
Apoptosis
BCL2A1 BCL2-related protein A1 Inhibition of apoptosis 0.57
Immune response
CCL4 Chemokine (C-C motif) ligand 4 Inflammatory response 0.33
CD83 CD83 molecule Humoral response 0.67
TNF-R: responders to anti-TNF therapy; TNF-NR: nonresponders to anti-TNF therapy.
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activity, potentially useful in cancer therapy37, these agents
could be potential drugs for RA therapy.
The CCL4 and CD83 genes were also downregulated in
responders to anti-TNF agents compared with nonresponders
(Table 4). CCL4 (MIP1-ß) is a potent chemoattractant to T
cells and natural killer cells, antigen-presenting cells, and
monocytes, and it appears to have an important proinflamma-
tory role in RA38. Given that patients with RA present with
elevated CCL4 levels39 and that CCL4 is upregulated in MTX
and MTX plus anti-TNF agent nonresponders, this chemokine
may be further considered as a potential target for these
patients. CD83 is a surface marker of dendritic cell matura-
tion, and it has been shown to take part in the activation of T
cells and B cells40,41. Given that a T cell activation molecule
is upregulated in nonresponders to MTX and anti-TNF agents,
this molecule may be a potential marker for nonresponders,
meriting further studies. These results suggest that nonrespon-
ders to MTX plus anti-TNF agents exhibit a proinflammatory
profile, characterized by increased lymphomononuclear
chemoattractants (CCL4), activated lymphocytes, and anti-
gen-presenting cells (CD83), and that nonresponders to MTX
monotherapy exhibit increased expression of antiapoptotic
genes (BCL2A1, MXD1, TNIP1, and BTG2) and decreased
expression of proapoptotic genes (HTRA2, CAV1, CASP8AP2,
and PRKDC) in addition to the increase in CCL4 expression.
Conversely, in a similar study evaluating the transcription pro-
files of PBMC of responders and nonresponders to anti-TNF
agents, Juliá, et al reported 8 genes that could be used as mod-
els for predicting the response to anti-TNF agents; 3 of them
(GNLY, SLC2A3, and MXD4) are associated with apoptosis
mechanisms42.
Our work confirms growing knowledge about apoptosis as
a key mechanism in the response to anti-TNF agents, driven
by the modulation of proapoptotic Bcl-2 family and caspase
activity, as recently reviewed43.
One could argue that use of anti-TNF agents is restricted to
infliximab. We chose only 1 drug and only 1 mechanism of
action to ensure that the findings in our study could not be
attributed to other anti-TNF agent. The gene expression pro-
file of patients using etanercept has already been assessed.
Koczan, et al, evaluating 19 patients with RA in a synthetic
DMARD and corticosteroid uncontrolled study, described the
cDNA microarray as a useful tool to predict clinical response
to etanercept after 3 months of treatment13 using an 8-gene
model, including CCL4. The cDNA microarray showed 42
differentially expressed genes between responders and non -
responders to etanercept. Similar to our results, these genes
were found to be involved in regulation of transcription, sig-
nal transduction, immune response, metabolism, and protein
binding and transport. Thus, we suppose that the modulated
genes can vary when different anti-TNF agents are used, but
the biological processes involved seem to be similar.
With our study of the gene expression profiles of RA
PBMC, it was possible to distinguish responders from non -
responders to MTX and responders and nonresponders to
MTX plus anti-TNF agents. We also found candidate genes
relating to mechanisms of disease and treatment possibilities
that should be studied further.
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